Almac Clinical Services, part of the Almac Group, said with the growth of biopharmaceutical development and clinical trials there has been an evolution in trial designs to match these targeted therapies that pose additional challenges.
“The clinical trial landscape is experiencing rapid growth in biologics and personalized medicine. Our clients are faced with increasing challenges to overcome, which have resulted in aggressive study timelines, rising costs, the need for supply chain flexibility and the necessity to supply smaller, yet more global, clinical studies for specifically targeted populations,” an Almac spokesperson told us.
The new solution is a secondary packaging and labeling approach in which an operation is triggered by a distribution order and is sent directly to the patient or trial site.
The Almac spokesperson said the solution can reduce the supply cycle time to provide a ‘tighter control’ of supply including full late-stage customization of clinical supply kits to increase efficiency across the entire clinical supply chain.